Management of Advanced Non-Small Cell Lung Cancer (NSCLC) and Clinical Outcomes in Patients Who Received Gefitinib in Thailand

Completed

• Conditions: Lung Cancer

• Registration Number: NCT01130961
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to determine progression-free survival of lung cancer patients who received gefitinib in clinical practice in Thailand.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-10
• Study First Submitted: 2010-04-29
• Study First Submitted QC: 2010-05-25
• Study First Posted: 2010-05-26
• Primary Completion: 2010-08
• Study Completion: 2010-08
• Status Verified: 2010-10
• Last Update Submitted: 2010-10-06
• Last Update Posted: 2010-10-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

• Diagnosed as having lung cancer based on histological/cytological findings
• Admitted to the hospital between January 2004 and December 2008
• Treated with gefitinib for at least 3 months

Exclusion Criteria

• Involvement in the planning and/or conduct of the study
• Participation in another clinical study during the last 3 months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression-free survival	median time from the first date of treatment until date of disease progression during Jan 2004- Dec 2008 or 5 years approx.

Secondary Outcome Measures

Name	Time	Method
Prevalence of EGFR & KRAS mutation from laboratory result	During Jan 2004- Dec 2008 or 5 years approx.
Time to maximum response	Median time from the first date of treatment until the date that the disease can be maximum controlled during Jan 2004- Dec 2008 or 5 years approx.
Overall survival	time from the first date of treatment until date of patients dead during Jan 2004- Dec 2008 or 5 years approx.

Trial Locations

Locations (1)

Research Site; 🇹🇭 Bangkok, Thailand